The ABPI has announced that the pharmaceutical industry will give the NHS Scotland £70 million, or £1 million a week, to fund new medicines.
List view / Grid view
The Scottish Medicines Consortium has published advice accepting three new medicines for routine use...
The SMC endorses routine prescribing across NHS Scotland of Ipsen’s cabozantinib, offering a new therapy option to help battle kidney cancer.
9 August 2016 | By Novo Nordisk
The drug was approved using evidence from three phase III studies in adults with type 1 diabetes mellitus and five phase III studies in adults with type 2 diabetes mellitus. The researchers discovered that insulin degludec was non-inferior to other long-acting insulin analogues, assessed by the mean change in glycosylated…